The first design and synthesis of [11C]MKC-1 ([11C]Ro 31-7453), a new potential PET cancer imaging agent

Min Wang, Mingzhang Gao, Kathy D. Miller, George W. Sledge, Gary D. Hutchins, Qi Huang Zheng

Research output: Contribution to journalArticlepeer-review

10 Scopus citations


Bisindolylmaleimide MKC-1 (formerly known as Ro 31-7453) is a novel, orally active, small-molecule, cell cycle inhibitor with broad-spectrum antitumor effects. [11C]MKC-1 ([11C]Ro 31-7453) was first designed and synthesized as a new potential positron emission tomography cancer imaging agent through two different strategies. The first strategy was to prepare a carbon-11-labeled bisindolyl maleic anhydride intermediate followed by the conversion to maleimide. The second strategy involved the condensation of either carbon-11-labeled indole-3-acetamides with indole-3-glyoxalates, or indole-3-acetamides with carbon-11-labeled indole-3-glyoxalates. The radiochemical yields were 15-30%, decay corrected to end of bombardment (EOB), based on [11C]CO2. The specific activity was 222-296 GBq/μmol at EOB and 111-148 GBq/μmol at the end of synthesis, respectively.

Original languageEnglish (US)
Pages (from-to)763-775
Number of pages13
JournalNuclear Medicine and Biology
Issue number7
StatePublished - Oct 2010


  • [C]MKC-1 ([C]Ro 31-7453)
  • Cancer imaging
  • Positron emission tomography
  • Radiosynthesis

ASJC Scopus subject areas

  • Cancer Research
  • Molecular Medicine
  • Radiology Nuclear Medicine and imaging

Fingerprint Dive into the research topics of 'The first design and synthesis of [<sup>11</sup>C]MKC-1 ([<sup>11</sup>C]Ro 31-7453), a new potential PET cancer imaging agent'. Together they form a unique fingerprint.

Cite this